S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:CGTX

Cognition Therapeutics (CGTX) Stock Price, News & Analysis

$1.82
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$1.78
$1.88
50-Day Range
$1.78
$2.53
52-Week Range
$0.90
$3.49
Volume
187,321 shs
Average Volume
234,281 shs
Market Capitalization
$70.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

Cognition Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
266.3% Upside
$6.67 Price Target
Short Interest
Healthy
1.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Cognition Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$9,975 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.10) to ($2.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.08 out of 5 stars

Medical Sector

387th out of 939 stocks

Biological Products, Except Diagnostic Industry

60th out of 158 stocks

CGTX stock logo

About Cognition Therapeutics Stock (NASDAQ:CGTX)

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

CGTX Stock Price History

CGTX Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
A Preview Of Cognition Therapeutics's Earnings
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
See More Headlines
Receive CGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2021
Today
3/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CGTX
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.67
High Stock Price Target
$9.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+266.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-21,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.39 per share

Miscellaneous

Free Float
29,718,000
Market Cap
$70.98 million
Optionable
Not Optionable
Beta
1.67
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

CGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Cognition Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cognition Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGTX shares.
View CGTX analyst ratings
or view top-rated stocks.

What is Cognition Therapeutics' stock price target for 2024?

3 analysts have issued 1 year price objectives for Cognition Therapeutics' stock. Their CGTX share price targets range from $5.00 to $9.00. On average, they predict the company's stock price to reach $6.67 in the next year. This suggests a possible upside of 266.3% from the stock's current price.
View analysts price targets for CGTX
or view top-rated stocks among Wall Street analysts.

How have CGTX shares performed in 2024?

Cognition Therapeutics' stock was trading at $1.85 at the beginning of the year. Since then, CGTX shares have decreased by 1.6% and is now trading at $1.82.
View the best growth stocks for 2024 here
.

When is Cognition Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CGTX earnings forecast
.

How were Cognition Therapeutics' earnings last quarter?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) issued its quarterly earnings results on Tuesday, November, 16th. The company reported ($8.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $7.55.

When did Cognition Therapeutics IPO?

Cognition Therapeutics (CGTX) raised $45 million in an initial public offering on Friday, October 8th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share.

Who are Cognition Therapeutics' major shareholders?

Cognition Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Pathstone Holdings LLC (6.87%), Vanguard Group Inc. (2.25%), Vanguard Group Inc. (2.25%), Kestra Advisory Services LLC (0.68%), Mercer Global Advisors Inc. ADV (0.41%) and Twin Focus Capital Partners LLC (0.29%). Insiders that own company stock include Ellen B Richstone, Lisa Ricciardi and Peggy Wallace.
View institutional ownership trends
.

How do I buy shares of Cognition Therapeutics?

Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners